Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLKL | Q8NB16 | 4/20 | 0.50 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | ALPI | P09923 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12065619 | 0.87 | IDO1 (0.38) | MLKLSCN10AIDO1ALPLALPI | |
| SCHEMBL14762836 | 0.86 | MLKL (0.48) | MLKLSCN10AALPLALPIALPG | |
| SCHEMBL12066562 | 0.85 | MLKL (0.46) | MLKLSCN10AALPLALPIALPG | |
| SCHEMBL12065632 | 0.84 | MLKL (0.46) | MLKLSCN10AKDM4ERAB9APDE2A | |
| SCHEMBL12065613 | 0.81 | ALPL (0.47) | MLKLSCN10AIDO1ALPLALPI | |
| SCHEMBL12065630 | 0.79 | MLKL (0.41) | MLKLSCN10AALPLALPIALPG | |
| SCHEMBL14770500 | 0.78 | MLKL (0.38) | MLKLSCN10AALPLALPIALPG | |
| SCHEMBL12066570 | 0.77 | MLKL (0.44) | MLKLALPLALPIALPGPDE2A | |
| SCHEMBL12066013 | 0.77 | SCN10A (0.40) | MLKLSCN10AALPLALPIALPG | |
| SCHEMBL12065257 | 0.76 | MLKL (0.39) | MLKLSCN10AIDO1BRD4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | claimed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | claimed |
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
| WO-2011148956-A1 | FUSED IMIDAZOLE DERIVATIVE | トーアエイヨー株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | MLKL 2378/4885SCN10A 85/4885IDO1 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.